Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

PubWeight™: 0.99‹?› | Rank: Top 15%

🔗 View Article (PMID 25775066)

Published in Ann Surg on January 01, 2016

Authors

Volkan Adsay1, Mari Mino-Kenudson, Toru Furukawa, Olca Basturk, Giuseppe Zamboni, Giovanni Marchegiani, Claudio Bassi, Roberto Salvia, Giuseppe Malleo, Salvatore Paiella, Christopher L Wolfgang, Hanno Matthaei, G Johan Offerhaus, Mustapha Adham, Marco J Bruno, Michelle D Reid, Alyssa Krasinskas, Günter Klöppel, Nobuyuki Ohike, Takuma Tajiri, Kee-Taek Jang, Juan Carlos Roa, Peter Allen, Carlos Fernández-del Castillo, Jin-Young Jang, David S Klimstra, Ralph H Hruban, Members of Verona Consensus Meeting, 2013

Author Affiliations

1: *Department of Pathology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA †Department of Pathology, Massachusetts General Hospital, Boston, MA ‡Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan §Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY ¶Department of Pathology, University of Verona, Verona, Italy ||Department of Surgery, Massachusetts General Hospital, Boston, MA **Department of Surgery, University of Verona, Verona, Italy ††Department of Surgery, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD ‡‡Departments of Surgery, University of Bonn, Bonn, Germany §§Departments of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands ¶¶Department of Surgery, Edouard Herriot Hospital, HCL, Lyon, France ||||Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands ***Departments of Pathology, Technical University, Munich, Germany †††Department of Pathology, Showa University Fujigaoka Hospital, Yokohama, Japan ‡‡‡Department of Pathology, Tokai University Hachioji Hospital, Tokyo, Japan §§§Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea ¶¶¶Department of Pathology, Pontificia Universidad Católica de Chile, Santiago, Chile ||||||Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY ****Department of Surgery, Massachusetts General Hospital, Boston, MA ††††Department of Surgery, Seoul National University Hospital, Seoul, Korea ‡‡‡‡Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.

Articles citing this

A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol (2015) 1.09

Morphological differentiation and follow-up of pancreatic cystic neoplasms using endoscopic ultrasound. Endosc Ultrasound (2015) 0.87

Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun (2015) 0.77

Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Pancreas: Clinicopathologic Analysis of 38 Cases Highlights a More Protracted Clinical Course Than Currently Appreciated. Am J Surg Pathol (2016) 0.76

Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch (2016) 0.76

Interobserver variability in intraductal papillary mucinous neoplasm subtypes and application of their mucin immunoprofiles. Mod Pathol (2016) 0.75

Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases. Am J Surg Pathol (2016) 0.75

Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. J Cancer (2016) 0.75

A Rare Case of Intraductal Papillary Mucinous Neoplasm of the Biliary Duct in a Patient with Prostate Adenocarcinoma. Case Rep Gastroenterol (2016) 0.75

Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol (2017) 0.75

Clinicopathological Features of Intraductal Papillary Mucinous Neoplasms of Pancreas in a Tertiary Care Center: A 14 Year Retrospective Study. J Clin Diagn Res (2016) 0.75

Cystic Neoplasm of the Pancreas. Indian J Surg (2015) 0.75

Articles cited by this

(truncated to the top 100)

The Vienna classification of gastrointestinal epithelial neoplasia. Gut (2000) 9.39

International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83

International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22

Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12

Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg (2004) 5.09

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03

An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74

Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87

Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology (2007) 2.96

Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76

Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76

Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg (2012) 2.58

Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg (2009) 2.33

Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg (1999) 2.33

Redefining the R1 resection in pancreatic cancer. Br J Surg (2006) 2.30

Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology (1991) 2.14

Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol (2006) 2.12

Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg (2007) 2.10

Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep (2011) 2.09

Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg (2008) 2.04

Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg (2011) 2.02

Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96

Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol (2005) 1.95

Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut (2011) 1.94

Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut (2006) 1.91

Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg (2007) 1.86

Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol (2010) 1.83

Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol (1996) 1.82

Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer (2002) 1.82

High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Arch Surg (2006) 1.78

Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas (2004) 1.76

Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer (2004) 1.75

European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis (2013) 1.75

Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg (2010) 1.73

Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer (2002) 1.69

Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2008) 1.68

The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol (2002) 1.68

Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas. Pancreatology (2002) 1.67

Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res (2009) 1.65

Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol (2002) 1.59

Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg (2013) 1.58

The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg (2004) 1.57

Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol (2003) 1.57

Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg (2010) 1.56

Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch (1994) 1.54

New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol (2002) 1.54

Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg (2001) 1.53

The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol (2001) 1.48

Intraductal papillary neoplasms of the pancreas. A clinicopathologic study of six patients. Cancer (1989) 1.48

Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Oncol (2013) 1.47

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol (2006) 1.46

"Ductectatic" mucinous cystadenoma and cystadenocarcinoma of the pancreas. Radiology (1986) 1.41

Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol (2001) 1.40

Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg (2007) 1.39

Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut (2010) 1.35

Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol (2010) 1.35

Pancreatic tumors with cystic dilatation of the ducts: intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms. Semin Diagn Pathol (2000) 1.35

Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg (2007) 1.34

Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33

Mucinous cystic neoplasms of the pancreas. Semin Diagn Pathol (2000) 1.33

Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Mod Pathol (2008) 1.33

Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol (2013) 1.32

Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg (2007) 1.30

The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol (2000) 1.26

Intraductal papillary mucinous neoplasm. Hum Pathol (2011) 1.26

Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas (2011) 1.25

Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol (2007) 1.24

Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Semin Diagn Pathol (2012) 1.23

Mucin-producing tumor of the pancreas. Cancer (1991) 1.23

Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg (2012) 1.22

Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg (2008) 1.22

Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol (2010) 1.19

Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2009) 1.18

Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are ≥1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases. Am J Surg Pathol (2012) 1.17

Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol (2003) 1.16

Ductectatic-type mucinous cystadenoma and cystadenocarcinoma of the human pancreas: a novel clinicopathological entity. Jpn J Cancer Res (1993) 1.16

Intraductal papillary mucinous neoplasms of the pancreas showing fistula formation into other organs. J Gastroenterol (2010) 1.15

Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology (2006) 1.15

Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas (2010) 1.14

Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig Surg (1999) 1.14

Should we do EUS/FNA on patients with pancreatic cysts? The incremental diagnostic yield of EUS over CT/MRI for prediction of cystic neoplasms. Pancreas (2013) 1.14

Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol (2010) 1.13

Redefining resection margin status in pancreatic cancer. HPB (Oxford) (2009) 1.12

Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol (2013) 1.11

Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg (2014) 1.11

Paraduodenal pancreatitis: a clinico-pathologically distinct entity unifying "cystic dystrophy of heterotopic pancreas", "para-duodenal wall cyst", and "groove pancreatitis". Semin Diagn Pathol (2004) 1.11

Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. Hepatogastroenterology (1999) 1.09

Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. Pancreatology (2008) 1.08

Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg (2011) 1.07

Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas (2013) 1.07

Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist (2010) 1.06

MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol (2006) 1.05

Utility of the sendai consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review. J Gastrointest Surg (2014) 1.05

Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg (2011) 1.05

Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation. Ann Surg (2005) 1.04

Intraductal tubular neoplasms of the pancreas: histogenesis and differentiation. Pancreas (2005) 1.04

Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas (2007) 1.04

Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas (2010) 1.02

Chronic pancreatitis: evolution of the disease. Hepatogastroenterology (1991) 1.02

Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol (2011) 1.02

Articles by these authors

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02

International network of cancer genome projects. Nature (2010) 20.35

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40

Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94

The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26

Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med (2010) 10.21

ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70

Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01

Pancreatic cancer. Lancet (2011) 8.54

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41

Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03

Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. N Engl J Med (2007) 7.56

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35

International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18

Pancreatic cancer. Annu Rev Pathol (2008) 6.96

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65

Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78

An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52

Early versus on-demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med (2014) 5.42

Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36

Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12

Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg (2004) 5.09

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03

Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83

An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72

Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72

Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol (2008) 4.70

Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60

International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas (2011) 4.56

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38

Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum (2012) 4.27

Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22

Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21

Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12

Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99

Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96

PEComas: the past, the present and the future. Virchows Arch (2007) 3.93

Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83

Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg (2002) 3.82

Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51

mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51

Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49

IAP Guidelines for the Surgical Management of Acute Pancreatitis. Pancreatology (2002) 3.48

Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42

Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42

Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39

Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31

Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.28

ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23

Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14

Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10

International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut (2012) 3.09